Takara Bio
Takara Bio is a biotechnology company dedicated to advancing gene and cell research, developing innovative therapies, and providing research reagents, scientific instruments, and CDMO services. The company aims to contribute to health and well-being through its cutting-edge research and development activities.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Products
Research reagent product portfolio
Catalog of laboratory reagents and consumables for molecular biology research.
Laboratory automation and instruments
Scientific instruments and automation platforms to support sample handling and workflow automation.
AAV vector platform for inner-ear gene transfer
AAV-based vector platform developed for efficient gene delivery to inner ear tissues (platform described in company announcement).
TCR-based gene therapy candidate (NY-ESO-1 target)
TCR-based gene therapy candidate targeting the NY-ESO-1 antigen, with reported clinical study results in a peer-reviewed journal.
Research reagent product portfolio
Catalog of laboratory reagents and consumables for molecular biology research.
Laboratory automation and instruments
Scientific instruments and automation platforms to support sample handling and workflow automation.
AAV vector platform for inner-ear gene transfer
AAV-based vector platform developed for efficient gene delivery to inner ear tissues (platform described in company announcement).
TCR-based gene therapy candidate (NY-ESO-1 target)
TCR-based gene therapy candidate targeting the NY-ESO-1 antigen, with reported clinical study results in a peer-reviewed journal.
Services
End-to-end development and manufacturing services for biologics, gene and cell therapy candidates, including process support and production capacity.
Manufacture of mRNA vaccine components and enzymes required for mRNA production in a dedicated facility.
Production and distribution of molecular biology reagents and consumables for research laboratories.
Provision and integration of scientific instruments and automation systems to support laboratory workflows.
Collaborative R&D and partner-based development programs for gene therapy candidates, including AAV-based approaches.
End-to-end development and manufacturing services for biologics, gene and cell therapy candidates, including process support and production capacity.
Manufacture of mRNA vaccine components and enzymes required for mRNA production in a dedicated facility.
Production and distribution of molecular biology reagents and consumables for research laboratories.
Provision and integration of scientific instruments and automation systems to support laboratory workflows.
Collaborative R&D and partner-based development programs for gene therapy candidates, including AAV-based approaches.
Expertise Areas
- AAV gene therapy development
- mRNA ingredient and enzyme manufacturing
- Contract development and manufacturing (CDMO)
- Research reagent manufacturing and distribution
Key Technologies
- AAV vector engineering
- mRNA synthesis and enzymology
- Viral vector manufacturing
- TCR-based gene therapy methods
News & Updates
IR information regarding matters concerning controlling shareholders.
News release about the redesign of the regulatory strategy for NY-ESO-1・siTCR™ gene therapy in Japan.
IR notice for the 23rd annual general meeting of shareholders.
IR notice about changes in the company's representative directors.
IR notice regarding dividend from surplus.
Additional news release about the gene therapy strategy.
IR information regarding matters concerning controlling shareholders.
News release about the redesign of the regulatory strategy for NY-ESO-1・siTCR™ gene therapy in Japan.
IR notice for the 23rd annual general meeting of shareholders.
IR notice about changes in the company's representative directors.
IR notice regarding dividend from surplus.
Additional news release about the gene therapy strategy.